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Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, New YorkABSTRACT Store-operated calcium entry (SOCE) is an important Ca2þ entry pathway in skeletal muscle. However, direct
electrophysiological recording and full characterization of the underlying SOCE current in skeletal muscle cells (ISkCRAC) has
not been reported. Here, we characterized the biophysical properties, pharmacological profile, and molecular identity of ISkCRAC
in skeletal myotubes, as well as the regulation of its rate of activation by temperature and the type I ryanodine receptor (RyR1).
ISkCRAC exhibited many hallmarks of Ca
2þ release activated Ca2þ currents (ICRAC): store dependence, strong inward rectifica-
tion, positive reversal potential, limited cesium permeability, and sensitivity to SOCE channel blockers. ISkCRAC was reduced by
siRNA knockdown of stromal interaction molecule 1 and expression of dominant negative Orai1. Average ISkCRAC current
density at 80mV was 1.00 5 0.05 pA/pF. In the presence of 20 mM intracellular EGTA, ISkCRAC activation occurred over
tens of seconds during repetitive depolarization at 0.5Hz and was inhibited by treatment with 100 mM ryanodine. The rate of
SOCE activation was reduced threefold in myotubes from RyR1-null mice and increased 4.6-fold at physiological temperatures
(35–37C). These results show that ISkCRAC exhibits similar biophysical, pharmacological, and molecular properties as ICRAC
in nonexcitable cells and its rate of activation during repetitive depolarization is strongly regulated by temperature and
RyR1 activity.INTRODUCTIONCa2þ plays a central role in a multitude of cellular events.
Depending on cell type, entry of extracellular Ca2þ into
the cell can occur through several distinct pathways,
including but not limited to, voltage-gated Ca2þ channels,
receptor-operated Ca2þ channels, and store-dependent
pathways, including Ca2þ release activated Ca2þ (CRAC)
channels in nonexcitable cells (1) and store-operated
calcium entry (SOCE) channels in skeletal (2–5), cardiac
(6), and smooth (7) muscle cells.
The molecular structure of CRAC/SOCE channels
consists of four pore forming-plasma membrane Orai1
subunits gated by Ca2þ store sensor stromal interaction
molecule 1 (STIM1) proteins located in the sarco- (SR) or
endoplasmic reticulum (1). Although Orai1 and STIM1
proteins are required to form fully functional SOCE chan-
nels within the transverse tubule system of skeletal muscle
cells (4,8,9), other factors and proteins that influence Ca2þ
store depletion, STIM1 Ca2þ sensitivity, and Orai1 channel
activation may regulate SOCE in skeletal muscle. For
example, SOCE dysfunction and an increase in muscle fati-
gability are observed in skeletal muscle cells lacking either
mitsugumin29 (MG29) or both the type 1 and type 3 ryano-
dine receptors (RyR1 and RyR3, respectively) (3).
Prior measurements of SOCE in skeletal muscle cells
have primarily been conducted using indirect methods
(e.g., rates of Ca2þ entry and Mn2þ quench using Ca2þ
sensitive dyes). More direct electrophysiological character-
ization of SOCE in skeletal muscle remains controversial.Submitted November 22, 2011, and accepted for publication June 4, 2012.
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0006-3495/12/07/0202/10 $2.00Initial attempts to measure single SOCE channel activity
in skeletal muscle fibers resulted in a detection of a channel
with a conductance of 7–8 pS (10). However, substantial
activity of these channels was observed under basal condi-
tions and channel open probability was increased only
~4-fold following SR Ca2þ depletion. In addition, these
channels were recorded from the pipette-accessible surface
membrane (not within the transverse tubule system) and
exhibited a weak sensitivity to SOCE/CRAC channels
blockers (10). Thus, the actual identity of the 7–8 pS
channels remains unclear. A more recent study failed to
detect either single channel or whole-cell SOCE currents
in adult mouse skeletal muscle fibers, challenging the phys-
iological significance of SOCE in skeletal muscle (11).
Thus, direct electrophysiological recording of SOCE
channel activity in muscle cells, as well as a rigorous
biophysical, pharmacological, and molecular characteriza-
tion of the underlying current is needed.
In addition to being a Ca2þ store sensor, STIM1 was also
recently shown to serve as a temperature sensor (12). Specif-
ically, STIM1 multimerization and Orai1 channel coupling
is strongly temperature dependent such that a transient
increase in temperature promotes STIM1 clustering that
can lead to SOCE channel activation upon cooling. Measure-
ment of SOCE channel currents in muscle cells at physiolog-
ical temperatures has not been reported, which has
significantly limited progress in elucidating the physiolog-
ical role, biophysical properties, and activation rate of
SOCE in skeletal muscle. In addition, SOCE dysfunction
may contribute to muscle fatigue (3), muscle weakness in
aging (13,14), muscular dystrophy (15), and the pathophys-
iology ofmalignant hyperthermia (MH) (16,17), a potentiallyhttp://dx.doi.org/10.1016/j.bpj.2012.06.001
Regulation of SOCE Activation in Myotubes 203deadly pharmacogenic disorder in which volatile anesthetics
and depolarizing relaxants trigger uncontrolled muscle
contractions in susceptible individuals that occur coincident
with a dramatic rise in core body temperature (18). Given this
backdrop, direct biophysical and pharmacological character-
ization of the underlying SOCE current in skeletal muscle
cells and assessment of its regulation by physiological
factors including repetitive stimulation, temperature, and
RyR1 function is of critical importance.
We hypothesized that the rate of SOCE activation
depends on SR depletion, which is regulated by temperature
and RyR1 Ca2þ release during repetitive stimulation. To
evaluate the validity of this hypothesis, we used the
whole-cell patch clamp technique to directly monitor the
biophysical/pharmacological properties and kinetics of
activation of the macroscopic Ca2þ release-activated Ca2þ
current in skeletal muscle myotubes derived from normal
and RyR1-null mice (referred to here as ISkCRAC). ISkCRAC
was activated by promoting store depletion through the
use of repetitive voltage clamp depolarization under condi-
tions in which SR Ca2þ reuptake was inhibited (e.g., either
by extracellular addition of thapsigargin (Tg), a sarco-endo-
plasmic reticulum Ca2þ ATPase (SERCA) pump inhibitor,
or inclusion of a high concentration of intracellular EGTA
in the patch pipette internal solution). We also compared
ISkCRAC properties and kinetics of activation during repeti-
tive depolarization at room and physiological (~37C)
temperatures. Our results show that activation of ISkCRAC
in primary skeletal myotubes during repetitive depolariza-
tion depends strongly on both temperature and RyR1 Ca2þ
release channel function.MATERIALS AND METHODS
Ethical approval
All animals were housed in a pathogen-free area at the University of
Rochester and animal protocols carried out in accordance with procedures
reviewed and approved by the local University Committee on Animal
Resources.Primary myotube cultures, siRNA transfection,
and nuclear injection of Orai1 mutant cDNA
Myotubes derived from normal and RyR1-null (dyspedic) mice were
prepared as previously described (19). Electrophysiological experiments
were performed on individual myotubes from 8- to 11-day-old cultures.
Transfection of murine STIM1 siRNA (Dahrmacon, Chicago, IL) was
conducted 2 days after initial plating of myoblasts using Lipofectamine
2000 (Invitrogen, Carlsbad, CA) and did not produce a detectable change
in myotube formation or differentiation (4). Transfection of a scrambled
siRNA was used as control. Nuclear injection of myotubes with cDNA
(0.1 mg ml1) encoding dominant-negative (E106Q) Orai1 (dnOrai1) was
performed 5 days after myoblast plating with patch clamp experiments
conducted 3 days later (4). Nuclear injections also included a cDNA encod-
ing CD8 (0.05 mg ml1) to allow for subsequent identification of injected
myotubes with CD8 antibody-coated beads (4).Western blot analysis
Cultured myotubes were harvested 5–6 days after transfection of STIM1
small interfering RNAs (siRNAs). STIM1 protein was separated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis on a 10% gel. Nonspe-
cific binding was blocked for 1 h with 5% milk in a Tris-buffered saline
containing 0.15% Tween 20 (TBST). Membranes were incubated with
a rabbit anti-STIM1 (C-terminal) primary antibody (1:1000; Sigma-
Aldrich, St. Louis, MO) for 2 h in TBST containing 5% milk. Mouse
anti-glyceraldehyde-3-phosphate dehydrogenase (anti-GAPDH) primary
antibody (1:50,000; Ambion, Austin, TX) served as a loading control.
Membranes were washed three times with TBST and then incubated with
a secondary fluorescent conjugated DyLight antirabbit and antimouse anti-
bodies for STIM1 and GAPDH, respectively (1:10,000; Thermo Scientific,
Logan, UT) for 1 h in TBST containing 5% milk. Western blot quantifica-
tion of STIM1 knockdown was determined by densitometry using a
LI-COR Odyssey system and ImageJ 1.45s software (Wayne Rasband,
National Institute of Mental Health, Bethesda, MD).Whole-cell patch clamp recording
The whole-cell patch clamp technique was used to directly monitor ISkCRAC
in myotubes. Myotubes were voltage clamped at a holding potential of
80 mV. Recordings started 40 s after entering the whole-cell configuration
upon membrane rupture. Significant potassium current was not observed
even at the start of whole-cell recording (see þ40 mV voltage step shown
in Fig. S1 A in the Supporting Material). ISkCRAC voltage dependence was
obtained using a modification of the ramp protocol used widely for
measurement of ICRAC in nonexcitable cells (Fig. S1 A). Briefly, myotubes
were depolarized every 2 s with a voltage stimulus consisting of a 1 s step
to 0 mV (to both trigger depolarization-induced SR Ca2þ release and to
inactivate Naþ and T-type Ca2þ channels) followed by a 30 ms step
to þ40 mV (to further inactivate sodium channels and monitor outward
leak current), followed by a 200 ms voltage ramp from þ100 mV to
100 mV (1 mV/ms). ISkCRAC magnitude was quantified from the end of
a 65 ms step to80 mVat the end of each ramp protocol, a voltage in which
contamination due to any unblocked voltage-gated ion channels is minimal.
Whole-cell currents were recorded with an Axopatch 200A (Molecular
Devices, Sunnyvale, CA) amplifier and filtered at 2 kHz by an inline
four-pole Bessel filter. Data were digitized at 8.3 kHz using a DigiData
1200 interface (Molecular Devices). Capacitative currents were minimized
(>90%) using the capacitative transient cancellation feature of the ampli-
fier. Cell capacitance (Cm) was determined by integration of the capacity
transient resulting from aþ10-mV pulse applied from the holding potential
and was used to normalize ISkCRAC (pA/pF) obtained from different myo-
tubes. Data were collected at both room (21–23C, RT) and physiological
(35–37C, PT) temperatures.Recording solutions
Isolation of Ca2þ release-activated Ca2þ channel current in skeletal
myotubes (ISkCRAC) is complicated by the presence of a number of overlap-
ping voltage-gated ion channels. To minimize contribution of voltage-
gated channels, myotubes were bathed in an external recording solution
containing (in mM): 138 TEA-methanesulfonate, 10 CaCl2, 10 HEPES,
1 MgCl2, 0.1 nifedipine, pH ¼ 7.4 adjusted with tetraethylammonium-
hydroxice (TEA-OH). Patch pipettes (0.5–1.2 Mohm resistance) were filled
with an internal solution consisting of (in mM): 140 Cs-methanesulfonate,
10 HEPES, 20 Na-EGTA, 4 MgCl2, pH ¼ 7.4 adjusted with CsOH.
For some experiments, a low EGTA internal solution was used that con-
tained (in mM): 132 Cs-methanesulfonate, 10 HEPES, 0.1 Na-EGTA,
10 NaCl, 8 MgCl2, pH ¼ 7.4 adjusted with CsOH. L-type Ca2þ currents
were blocked by 100 mM nifedipine and identical results were also obtained
using either 3 mM nifedipine or 50 mM verapamil (Fig. S2), excludingBiophysical Journal 103(2) 202–211
204 Yarotskyy and Dirkseneffects of nifedipine on steady-state ISkCRAC. In some experiments, the
effects of 10 mM 2-aminoethoxydiphenyl borate (2-APB) on ISkCRAC
current density recorded at 80 mV was determined in the absence of
nifedipine.Offline data analysis
All data analyses were performed using Clampfit10 (Molecular Devices)
and Igor Pro 6 (WaveMetrics, Lake Oswego, OR) software suites. ISkCRAC
amplitude was determined by averaging the inward current during 20 ms of
the final 65 ms voltage step to 80 mV at the end of each ISkCRAC ramp
protocol. The time course of ISkCRAC activation was determined by plotting
ISkCRAC amplitude at the end of each ISkCRAC ramp protocol delivered every
2 s. A time-dependent increase in inward current at 80 mV, with little or
no change in outward current at þ40 mV, was used as a measure of activa-
tion of inwardly rectifying ISkCRAC (Fig. S1 A). Ramp currents obtained
before ISkCRAC activation or the first ramp current elicited upon establishing
whole-cell mode were used to subtract initial linear currents from sweeps
following ISkCRAC activation. ISkCRAC voltage dependence was obtained
from individual 200 ms voltage ramp sweeps (1 mV/ms) elicited during
each voltage protocol delivered at 0.5 Hz.
The time for 10% (T10%), 50% (T50%), and 90% (T90%) maximal
ISkCRAC activation during repetitive depolarization (0.5 Hz) was used as
an index for the speed of channel activation. The maximum rate of ISkCRAC
activation (dINorm/dt)Max was determined from the peak of the differential
for the time course of normalized ISkCRAC amplitude. All data are presented
as mean5 standard error of mean. Statistical significance (p < 0.05) was
determined using a Student’s two-tailed t-test. One-way analysis of vari-
ance, and Tukey’s post hoc test was used to test for differences among three
or more independent groups.Chemicals
N-(4-(3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)-4-methyl-1,2,3-
thiadiazole-5-carboxamide (BTP2) was purchased from Fisher Scientific
(Pittsburgh, PA). All other chemicals were purchased from Sigma-Aldrich.RESULTS
Biophysical, pharmacological, and molecular
characterization of ISkCRAC in skeletal myotubes
Direct measurement of SOCE current in skeletal myotubes
(ISkCRAC) is complicated by several factors, not the least
of which is the presence of multiple potential contaminating
voltage-dependent sodium, potassium, and calcium chan-
nels (8). We used specifically designed recording solutions
and voltage protocols (see Materials and Methods for
details) to isolate ISkCRAC in whole-cell voltage clamp
experiments in primary mouse myotubes (Fig. S1).
ISkCRAC was activated following depletion of SR Ca
2þ.
Two approaches were used to deplete SR Ca2þ and activate
ISkCRAC (Fig. 1). In the first approach, ISkCRAC was activated
by repetitive ramp depolarizations delivered at 0.5 Hz
during application of an extracellular recording solution
supplemented with 1 mM Tg, a potent and irreversible
inhibitor of SERCA pumps, and 30 mM caffeine (Caff),
an RyR agonist (Fig. 1, A and B). In these experiments, a
low EGTA-containing (0.1 mM) patch pipette internal solu-
tion was used. In the presence of Tg and Caff, Ca2þ releasedBiophysical Journal 103(2) 202–211during each depolarization is not recycled back into the SR,
resulting in progressive SR depletion with each pulse
leading to the activation of SOCE. Under these conditions,
a relatively slow activation of an inward current recorded
at 80 mV was observed that was inhibited by 10 mM
BTP2 (Fig. 1 A), a pyrazole derivative that inhibits both
CRAC channels (20) and TRPC3/5 channels (21).
Following activation with Tg and Caff, the voltage depen-
dence of the BTP2-sensitive macroscopic current exhibited
strong inward rectification and a very positive reversal
potential (Fig. 1 B), similar to that observed for ICRAC in
T lymphocytes (22,23). This current in skeletal myotubes
is referred to as ISkCRAC based on its dependence on store
depletion, strong inward rectification, positive reversal
potential, and sensitivity to organic and inorganic SOCE
channel blockers (see below).
The second approach used to activate ISkCRAC in myo-
tubes involved inhibition of SR Ca2þ reuptake during
repetitive ramp depolarization (0.5Hz) by inclusion of a
high concentration of a strong Ca2þ buffer (20 mM
EGTA) in the patch pipette internal solution (Fig. 1, C
and D). Under these recording conditions, a similar time-
dependent increase in an inwardly rectifying current was
observed at 80 mV and was markedly inhibited by both
10 mM BTP2 and 1 mM Gd3þ (Fig. 1, C and D). Subsequent
addition of 1 mM Tg and 10 mM Caff failed to further acti-
vate an additional inward current component (Fig. S3),
indicating that the two approaches for SOCE activation
were not additive. For all subsequent experiments, ISkCRAC
was activated using the high internal EGTA approach to
abrogate global calcium-dependent cytosolic events that
could potentially lead to Ca2þ-dependent inactivation of
SOCE (1).
It is well established that monovalent cations, including
Csþ ions, readily permeate TRPC and voltage-gated Ca2þ
channels in the absence of divalent cations (24–26).
However, a unique feature of Orai1 channels in nonexcit-
able cells is that they possess a narrow pore (1) that is
poorly permeable to Csþ ions in the absence of extracel-
lular divalent cations (27,28). To determine if this unique
permeation property is also a feature of SOCE channels
in myotubes, we determined the effect of exchanging
155 mM extracellular Csþ for 10 mM extracellular Ca2þ
and 138 mM TEAþ on ISkCRAC amplitude (Fig. 1, E and
F). Exchange of extracellular Csþ for Ca2þ and TEAþ
resulted in a rapid, near complete, and fully reversible inhi-
bition of ISkCRAC recorded at 80 mV. The results pre-
sented in Fig. 1 indicate that the biophysical properties
of ISkCRAC in myotubes are similar to that of ICRAC in T
lymphocytes.
The magnitude and pharmacological profile of the time-
dependent inward current recorded at 80 mV is summa-
rized in Fig. 2. Specifically, ISkCRAC recorded at 80 mV
was significantly inhibited by 5 mM and 10 mM BTP2
(Fig. 2 A), 1 mM and 100 mM Gd3þ (Fig. 2 B), 10 mM
FIGURE 1 Activation time course and biophys-
ical properties of ISkCRAC in normal myotubes.
(A and C) Representative time courses for ISkCRAC
activation measured at 80 mV during repetitive
ramp depolarization delivered at 0.5 Hz. (B and
D) Representative voltage dependence of ISkCRAC
for the times indicated in panels A and C. (A)
Time course for ISkCRAC activation during repeti-
tive ramp depolarization during application of
1 mM Tg and 30 mM Caff in the presence of a
low EGTA-containing pipette internal solution.
Following full activation, ISkCRAC was blocked
by addition of 10 mM BTP2. Arrows show time
points a, b, and c, used to illustrate ISkCRAC voltage
dependence as depicted in panel B. The dashed line
represents the zero current level and solid lines
show the time of drug application. (B) Strong
inwardly rectifying voltage dependence of ISkCRAC
for the time points shown in panel A. (C) Time
course for ISkCRAC activation during repetitive
ramp depolarization in the presence of 20 mM
EGTA in the patch pipette internal solution.
Following full activation, ISkCRAC was blocked
by addition of 1 mM Gd3þ. Arrows show time
points a, b, and c, used to illustrate ISkCRAC voltage
dependence as depicted in panel D. The dashed
line represents the zero current level and solid
line shows the time of Gd3þ application. (D)
Strong inwardly rectifying voltage dependence of
ISkCRAC for the time points shown in panel C. (E)
Representative time course for ISkCRAC activation
recorded at 80 mV under control conditions
(10 mM Ca2þ), following replacement with
155 mM Csþ (first solid line), and following
blockade with 10 mM BTP2 (second solid line).
(F) Bar graph depicting average (5SE) ISkCRAC
current density recorded at 80 mV in control
solution (Cntl, black bar), in the presence of
155 mM Csþ external solution, and after washout
with control external solution. *p < 0.05.
Regulation of SOCE Activation in Myotubes 2052-APB (Fig. 2 C, left), and 20 mM SKF 96365 (Fig. 2 C,
right). Interestingly, in contrast to ICRAC in nonexcitable
cells, ISkCRAC in myotubes exhibited ~100-fold lower
sensitivity to Gd3þ block (29,30). Data obtained from all
experiments in control myotubes revealed that average
ISkCRAC current density recorded at 80 mV was 1.00 5
0.05 pA/pF (n ¼ 90). Histogram analysis of ISkCRAC
current density at 80 mV from these experiments
exhibited a normal Gaussian distribution with a peak at
0.89 pA/pF and a standard deviation of 0.70 pA/pF
(Fig. 2 D).
A unique feature of CRAC channels is that low con-
centrations of 2-APB (e.g., 2–5 mM) increase channel
activity, whereas higher concentrations (R10 mM) produce
a transient increase followed by a sustained inhibition
(23). Surprisingly, under our standard recording condit-
ions, low concentrations of 2-APB (2 mM and 10 mM)
failed to activate ISkCRAC in myotubes (Fig. 2 C and
Fig. S4, C–F). The absence of 2-APB activation under
these conditions did not depend on whether ISkCRAC wasactivated by addition of Tg plus Caff or dialysis of a
high concentration of internal EGTA (Fig. S4 F). However,
we found that 10 mM 2-APB caused a transient facilita-
tion of ISkCRAC current density (recorded at 80 mV)
before a subsequent sustained inhibition when the current
was measured in the absence of nifedipine (Fig. S4, A
and B). Under these conditions, 10 mM 2-APB produced
a similar biphasic modulation of ISkCRAC as that observed
for ICRAC in T-lymphocytes channels (23). In contrast,
the relatively low sensitivity of ISkCRAC to Gd
3þ block
was not increased in the absence of nifedipine (data not
shown).
The low sensitivity to Gd3þ block indicates that the
molecular determinants of ICRAC and ISkCRAC may be
different. However, similar to ICRAC in T lymphocytes,
ISkCRAC in myotubes was also inhibited by both siRNA-
mediated STIM1 knockdown and the expression of
dominant negative E106Q Orai1 (Fig. 3). Specifically, trans-
fection of myotubes with STIM1 siRNAs resulted in a
comparable reduction in both STIM1 protein and ISkCRACBiophysical Journal 103(2) 202–211
FIGURE 2 ISkCRAC current density and pharma-
cology. (A) Bar graph depicting average (5SE)
ISkCRAC current density recorded at 80 mV in
control (Cntl, black bars) and after addition of
either 5 mM or 10 mM BTP2 (BTP2, open bars).
Numbers of paired experiments are shown in
bars. *p < 0.05. (B) Bar graph depicting average
(5SE) ISkCRAC current density recorded at
80 mV in control (Cntl, black bars) and after
addition of either 1 mM or 100 mM gadolinium
(Gd, open bars). *p < 0.05. (C) Bar graph depict-
ing average (5SE) ISkCRAC current density re-
corded at 80 mV in control (Cntl, black bars)
and after addition of either 10 mM 2-APB or
20 mM SKF 96365. *p < 0.05. (D) Histogram
distribution of all control peak ISkCRAC current
densities measured at 80 mV. The distribution
was fitted by a single Gaussian function with a
peak value centered at0.89 pA/pF and a standard
deviation of 0.7 pA/pF.
206 Yarotskyy and Dirksencurrent density measured at 80 mV (Fig. 3, A and B),
whereas ISkCRAC current density was undetectable in
E106Q-expressing myotubes (Fig. 3,C andD). These results
show that STIM1-Orai1 coupling underlies ISkCRAC activity
in myotubes.
Together, the results presented in Figs. 1–3 indicate that
ISkCRAC in primary skeletal myotubes exhibits similar,
though not identical, biophysical, pharmacological, andBiophysical Journal 103(2) 202–211molecular characteristics as those observed for ICRAC in T
lymphocytes (22,23).Rate of ISkCRAC activation is regulated by RyR1
activity
RyR1 plays an essential role in SR Ca2þ release during exci-
tation-contraction (EC) coupling (19) and is proposed toFIGURE 3 STIM1-Orai1 coupling underlies
ISkCRAC activity in myotubes. (A) Bar graph depict-
ing average (5SE) ISkCRAC current density re-
corded at 80 mV from myotubes transfected
with either scramble (SCR, black bar) or STIM1
siRNAs (STIM1 KD, open bar). Data were
obtained from 5 cells for each group. *p < 0.05.
(B) Western blot analysis for the culture used
for the experiments in A showing STIM1 expres-
sion (upper) in myotubes treated with SCR
or STIM1 siRNA (KD). GAPDH (lower) was
used as a loading control. (C) Representative
time courses for ISkCRAC activation measured at
80 mV during repetitive ramp depolarization
(0.5 Hz) obtained from a control (Cntl) myotube
and a myotube expressing E106Q dominant nega-
tive Orai1 (dnOrai1). (D) Bar graph depicting
average (5 SE) ISkCRAC current density recorded
at 80 mV from control myotubes (Cntl, black
bar) and myotubes expressing dnOrai1 (dnOrai1,
open bar). Data collected from 5 cells for each
group. *p < 0.05.
Regulation of SOCE Activation in Myotubes 207also play an important role in the regulation of SOCE in
skeletal myotubes (3,4,31). However, prior studies only
indirectly assessed the role of RyRs on SOCE. We found
that ISkCRAC was not activated by repetitive 0.5 Hz depolar-
ization in the presence of 0.1 mM EGTA and the absence of
SERCA blockade, though subsequent addition of Tg during
0.5 Hz stimulation resulted in the eventual activation of
ISkCRAC (Fig. S5). Thus, we compared ISkCRAC magnitude,
voltage dependence, and rate of activation under conditions
that manipulate RyR functionality and prevent SR Ca2þ re-
uptake (Figs. 4 and 5). First, ISkCRAC activation in the pres-
ence of high internal EGTA required repetitive ramp
depolarization as no inward current at 80 mV developed
over several minutes in the absence of repetitive depolariza-
tion (Fig. 4 A; n ¼ 4), whereas a robust BTP2-sensitive
inwardly rectifying current (Fig. 4 C; n ¼ 4) was readily
observed during this time frame in the presence of 0.5 Hz
stimulation. Similarly, ISkCRAC activation was not observed
during>2 min of repetitive ramp depolarization when RyRs
were blocked by pretreating myotubes with 100 mM ryano-
dine for 1 h (Fig. 4 B; n¼ 4). Together, these results indicate
that RyR-dependent Ca2þ release during repetitive depolar-
ization is required for time-dependent ISkCRAC activation in
the presence of high internal EGTA (Fig. 4 D).
To more specifically evaluate the role of RyR1 in ISkCRAC
activation during repetitive depolarization, we compared the
magnitude and rate of ISkCRAC activation in myotubes
derived from RyR1-null (dyspedic) and littermate control
mice (Fig. 5 A). First of all, peak ISkCRAC current density
induced by repetitive ramp depolarization in the presence
of high EGTA was significantly reduced in RyR1-deficient
myotubes (Fig. 5 B), consistent with prior reports (3,4).
Even more impressively, compared to control myotubes,
the rate of ISkCRAC activation during repetitive ramp depo-
larization was remarkably slowed (~10-fold) in dyspedic
myotubes (Fig. 5 C and D). The dramatic delay in ISkCRACactivation in dyspedic myotubes was assessed from the
times for 10% (T10%), 50% (T50%), and 90% (T90%) acti-
vation of maximal ISkCRAC. T10%, T50%, and T90% were
on average 15-, 8.4-, and 4.5-fold longer, respectively, in
dyspedic myotubes (Table S1). The maximum speed of
ISkCRAC activation was approximated by taking the peak
of the first derivative of the normalized ISkCRAC activation
time course (i.e., (dINorm/dt)Max). The maximal speed of
ISkCRAC activation was significantly (p < 0.05) reduced in
dyspedic myotubes (Fig. 5 D). Thus, both ISkCRAC magni-
tude and maximum rate of channel activation during repet-
itive ramp depolarization were significantly reduced in
RyR1-deficient myotubes. Together, the results in Figs. 4
and 5 indicate that RyR1 Ca2þ release plays an important
role in the magnitude and activation of ISkCRAC during
repetitive depolarizations, which is likely to have important
physiological implications during prolonged high frequency
stimulation of skeletal muscle (see Discussion).Rate of ISkCRAC activation is increased at
physiological temperature
Because STIM1 multimerization is strongly temperature
dependent (12) and SOCE dysfunction has been implicated
in malignant hyperthermia (16,17), we hypothesized that
the rate of ISkCRAC activation during repetitive depolariza-
tion is increased at elevated temperatures. To test the valid-
ity of this hypothesis, we compared ISkCRAC magnitude,
voltage dependence, and rate of activation in myotubes at
room (RT ¼ 21–23C) and physiological (PT ¼ 35–37C)
temperatures (Fig. 6). Myotubes from congenic C57Bl6
mice were used for these experiments. The rate of ISkCRAC
activation was significantly accelerated in myotubes main-
tained at a physiological temperature (Fig. 6 A). For the
experiment shown in Fig. 6 A, ISkCRAC at PT is already
nearly maximal at the time in which ISkCRAC only becomesFIGURE 4 RyR1 activity strongly influences
ISkCRAC activation during repetitive depolarization.
(A) Representative time course for ISkCRAC activa-
tion at 80 mV in the absence of repetitive
(0.5 Hz) ramp depolarization (no stimulation).
(B) Representative time course for ISkCRAC activa-
tion at80 mVobserved during repetitive (0.5 Hz)
ramp depolarization in the presence of 0.1 mM rya-
nodine. (C) Representative time course for ISkCRAC
activation at 80 mV observed during repetitive
(0.5 Hz) ramp depolarization in control recording
solution and following inhibition with 5 mM
BTP2. (D) Histogram depicting average (5SE)
ISkCRAC current density 60 s after initiation of
whole cell recording. Numbers of experiments
are shown in bars. Presence of repetitive stimula-
tion and ryanodine are indicated by þ.*p < 0.05.
n.s.; not significantly different.
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FIGURE 5 ISkCRAC activation during repetitive
depolarization is slowed in dyspedic myotubes.
(A) Representative time courses for activation of
normalized ISkCRAC (I/IMax) from normal (solid
circles) and dyspedic (open circles) myotubes.
The dashed line represents the zero current level.
(B) Average (5SE) peak ISkCRAC current density
at 80 mV was reduced in dyspedic myotubes.
(C) The average (5SE) time required for 10%
(T10%), 50% (T50%), and 90% (T90%) activation
of ISkCRAC was increased for dyspedic myotubes.
(D) Average (5SE) maximum rate of ISkCRAC
activation determined from the peak of the first
derivative of the I/IMax time course ((dINorm/dt)Max)
was reduced for dyspedic myotubes. *p < 0.05.
208 Yarotskyy and Dirksenfirst detectable at RT (~10 sec). Average values for T10%,
T50%, and T90% were all significantly (p < 0.05) reduced
at PT (Fig. 6 B and Table S2), consistent with a strong
temperature dependence for ISkCRAC activation. Indeed, the
maximal speed of ISkCRAC activation ([dINorm/dt]Max) was
>fourfold faster at PT compared to that observed at RT
(Fig. 6 C). Remarkably,>10% of maximal ISkCRAC was acti-
vated by just the second ramp depolarization at PT, resulting
in an average T10% slightly<1 s. These results indicate that
the formation of functional SOCE channel complexes can be
assembled in less than a few hundred milliseconds in myo-
tubes maintained at PT. Maximal ISkCRAC current density
was not significantly different between RT and 37C
(0.905 0.11 pA/pF, n ¼ 7 and 1.185 0.24 pA/pF, n ¼ 11Biophysical Journal 103(2) 202–211for RTand PT, respectively), consistent with the total number
of activated SOCE channels being similar at these two
temperatures. Moreover, the maximum speed of ISkCRAC
activation ((dINorm/dt)Max) in dyspedic myotubes was not
different at RT and PT, although the time required for 10%
(T10%) and 50% (T50%) activation of the current were
significantly reduced at PT.DISCUSSION
Characterization of ISkCRAC in myotubes
The primary objective of this study was to directly measure
the SOCE current in myotubes (ISkCRAC) and to characterizeFIGURE 6 Rate of ISkCRAC activation is
increased in myotubes at physiological tempera-
ture. (A) Representative time courses for activation
of normalized ISkCRAC (I/IMax) recorded either at
room temperature (RT, solid circles) or physiolog-
ical temperature (PT, open circles). The dashed
line represents the zero current level. (B) The
average (5SE) time required for 10% (T10%),
50% (T50%), and 90% (T90%) activation of
ISkCRAC was reduced at PT. Number of myotubes
are indicated in the inset. (C) Average (5SE)
maximum rate of ISkCRAC activation determined
from the peak of the first derivative of the I/IMax
time course ((dINorm/dt)Max) was increased at PT.
(D) Average (5SE) peak ISkCRAC current density
recorded at80 mV was not significantly different
between RT and PT. *p < 0.05.
Regulation of SOCE Activation in Myotubes 209the biophysical characteristics, pharmacological profile, and
molecular nature of the current. Our measurements of
ISkCRAC also enabled us for the first time to characterize
the kinetics of SOCE channel activation during repetitive
depolarization in muscle cells, as well as its dependence on
temperature and RyR activity. Our results show that ISkCRAC
activity depends on functional STIM1-Orai1 coupling, and
thus the biophysical properties and pharmacological signa-
ture of SkCRAC channels in myotubes are similar to that
of CRAC channels in T lymphocytes (22,23). Indeed, we
show that ISkCRAC inmyotubes is activated by store depletion
promoted by Ca2þ release during repetitive depolarization
when SR Ca2þ reuptake is inhibited either by prior treatment
with Tg or inclusion of a high concentration of EGTA in the
patch pipette. Consistent with that observed in T lympho-
cytes, ISkCRAC current density is relatively small (~1pA/pF
at 80 mV), which is ~10–15 times lower than peak
L-type Ca2þ current density recorded from myotubes under
comparable conditions (32). In addition, ISkCRAC recorded
in myotubes was significantly reduced by several well-
known CRAC channel inhibitors (including BTP2, gadoli-
nium, 2-APB, and SKF96365), exhibited strong inward
rectification, a positive reversal potential, low Csþ perme-
ability, and lacked a significant outward current component
at strong depolarizations (e.g., þ100 mV). The latter result
is different than that reported by Stiber et al. (8), the only
other study to report electrophysiological measurements of
ISkCRAC in myotubes. The reason for this difference is not
entirely clear, but may reflect greater leak current during
strong depolarization in the prior study.
The bimodal stimulatory and inhibitory effects of 10 mM
2-APB on ISkCRAC in the absence of nifedipine (Fig. S4) is
consistent with this current being determined by STIM1-
Orai1 coupling. However, an unexpected finding of this
study was that transient facilitation of ISkCRAC by 10 mM
2-APB was observed only in the absence of nifedipine.
Nifedipine was included in our standard myotube extracel-
lular recoding solution to enable measurement of ISkCRAC
voltage dependence in the absence of contaminating
L-type Ca2þ currents. Nevertheless, time-dependent activa-
tion of ISkCRAC during repetitive ramp depolarization in
myotubes can be assessed at 80 mV in the absence of
nifedipine because L-type Ca2þ channels close rapidly
(<1 ms) at this potential. To the best of our knowledge,
our finding that nifedipine masks 2-APB potentiation of
ISkCRAC is the first demonstration of a drug-drug interaction
in the pharmacological modulation of STIM1-Orai1 func-
tion. Future experiments are needed to determine if nifedi-
pine also masks 2-APB stimulation of CRAC currents in
nonmuscle cells and if the effects of nifedipine result from
either blocking 2-APB activation or from nifedipine
mimicking a sustained 2-APB potentiation of the current.
Despite the similarities between ISkCRAC and ICRAC, one
unique SkCRAC channel property was identified in our
experiments. ISkCRAC sensitivity to Gd
3þ block was rela-tively low, showing only ~50% block at 1 mM and requiring
up to 100 mM for complete block. These differences from
classic CRAC channel behavior are unexpected given the
dependence of ISkCRAC on STIM1-Orai1 coupling. One
possible explanation for the unique behavior of ISkCRAC is
that Orai1 channels in myotubes are activated in part by
coupling to the long splice isoform of STIM1 (STIM1L).
Consistent with this idea, McNally et al. (33) recently
demonstrated that high Ca2þ selectivity and other features
of the Orai1 channel pore is conferred by its interaction
with STIM1, which could conceivably manifest somewhat
differently for STIM1S versus STIM1L.
Our findings here that ISkCRAC depends on store depletion,
exhibits strong inward rectification, low Csþ permeability,
and is blocked by several known CRAC channel inhibitors
validates this current as the direct electrophysiological
correlate of SOCE in skeletal myotubes. Previous studies
have attempted to record SOCE channel activity in adult
skeletal muscle fibers. Ducret et al. (10) used cell-attached
patch clamp recordings from the surface membrane of adult
flexor digitorum brevis fibers to record single-channel
currents that exhibited a linear voltage dependence, a 7–8
picosiemens unitary conductance, and a fourfold increase
in open probability following treatment with Tg. However,
SOCE channels in adult muscle were subsequently shown
to be located deep within the transverse tubule system
(34), which is inaccessible to cell-attached patch electrodes.
In addition, Orai1 channels exhibit strong inward rectifica-
tion and a unitary conductance in the femtosiemens range,
well below that resolvable by single channel recording.
Thus, the single channel currents reported by Ducret et al.
were unlikely due to STIM1-Orai1-mediated channel
activity in the transverse tubule system. Allard et al. (11)
were unable to identify a specific unitary or whole-cell
conductance due to store depletion in flexor digitorum brevis
fibers isolated from adult mice. Thus, our measurements of
ISkCRAC in myotubes provide the first, to our knowledge,
complete biophysical, pharmacological, and molecular
characterization of SOCE currents in skeletal muscle cells.
Although ISkCRAC in myotubes may not directly correlate
with the corresponding SOCE channel conductance in adult
skeletal muscle fibers, previous measurements of SOCE in
adult muscle fibers using indirect imaging approaches have
revealed similar molecular and pharmacological properties
as those described here. Future work is needed to determine
if the electrophysiological approach described here is able to
directly measure a similar store-dependent conductance in
adult mammalian skeletal muscle fibers.The type I ryanodine receptor modulates ISkCRAC
magnitude and rate of activation
Our results show that RyR1-dependent SR Ca2þ depletion
triggers activation of SOCE in myotubes because ISkCRAC
did not develop in the absence of RyR1 Ca2þ release duringBiophysical Journal 103(2) 202–211
210 Yarotskyy and DirksenEC coupling (i.e., no depolarizations) or when RyR activity
was blocked by pretreatment with ryanodine. Our finding
that myotube dialysis with a high concentration of EGTA
in the absence of stimulation is not sufficient for SOCE acti-
vation is in good agreement with the results of Launikonis
and Rios (34) who showed that 5 mM BAPTA in zero Ca2þ
also failed to activate SOCE in fibers in the absence of
RyR1 stimulation measured indirectly as Ca2þ depletion
from sealed t-tubules. In addition, we found that ISkCRAC acti-
vation was markedly delayed in dyspedic myotubes, further
confirming a role for RyR1 Ca2þ release in SOCE activation
during repetitive depolarization. The reason for the very slow
time-dependent activation of ISkCRAC in EGTA-loaded dys-
pedic myotubes may reflect an elevated SR Ca2þ content in
dyspedic myotubes (35), reduced rate of RyR-independent
Ca2þ leak, or a combination of the two. Alternatively, slow
ISkCRAC activation in dyspedic myotubes might result from
a low level of SR Ca2þ leak through type 3 RyR channels
present inmyotubes or depolarization-dependent IP3 produc-
tion and subsequent IP3-mediated Ca
2þ release (36).
Our direct electrophysiological measurements of ISkCRAC
confirm a role for RyR1 in depolarization-dependent SOCE
channel function in myotubes as reported previously (3). By
extension to adult muscle fibers, our results suggest that
local store depletion at sites of RyR1 Ca2þ release (e.g.,
SR terminal cisternae) and subsequent activation of SOCE
channels in the adjacent t-tubular membrane could occur
during prolonged or repetitive high-frequency tetanic stim-
ulation. Moreover, our findings predict that activity-depen-
dent SR Ca2þ store depletion, and thus ISkCRAC activation,
should be significantly accelerated in muscle cells deficient
in calsequestrin1 (see (39)), the major SR Ca2þ binding
protein in skeletal muscle, or that express MH disease muta-
tions RyR1 that enhance SR Ca2þ leak (37,38).Temperature regulates the rate of ISkCRAC
activation
Direct electrophysiological measurements of ISkCRAC in
myotubes revealed that SOCE channel activation is a rela-
tively slowprocess atRT, taking~1min for completionduring
repetitive depolarization at 0.5 Hz (Figs. 5 C, 6 B, and Tables
S1 and S2; see also (8)). However, considerably faster rates of
SOCE activation would be expected to occur at higher
frequencies of activation (e.g., during 100 Hz tetani) and at
more physiological temperatures. Indeed, we found that the
maximum rate of ISkCRAC activation observed during 0.5 Hz
stimulationwas increased>fourfold at physiological temper-
atures (35–37C) (Fig. 6 C and Table S2). The observed
increase in ISkCRAC activation at physiological temperatures
could be due to a temperature-dependent increase in either
the rate of SR Ca2þ depletion, STIM1 multimerization,
STIM1/Orai1 coupling, or Ca2þ flux through activated
Orai1 channels. In this regard, Xaio et al. (12) recently re-
ported that STIM1 multimerization is strongly temperatureBiophysical Journal 103(2) 202–211dependent, which would promote a more rapid assembly of
functional STIM1-Orai1 channels and faster ISkCRAC activa-
tion.Whatever the underlyingmechanism, our demonstration
of a strong temperature-dependent increase in the rate of
ISkCRAC activation is in good agreement with recent observa-
tions that the Ca2þ permeability across the surface membrane
via SOCE is significantly increased at 39C in muscle fibers
following calsequestrin1 knockdown (39). Thus, future
studies are needed to determine the potential role of increased
temperature-dependent SOCE activation in the pathophysi-
ology of MH and other heat-related muscle disorders.CONCLUSION
The presence of SOCE in skeletal muscle is now well estab-
lished (2–5,8,9,13,14,34,39–42). The potential role of SOCE
in regulating the rate of skeletal muscle fatigue (3,8), differ-
entiation (43), its dependence on STIM1 and Orai1 coupling
(4,8), regulation by RyRs (3,31), and MG29 (3) have also
been reported previously. However, conclusions from all of
these studies have hinged almost entirely on indirect
measures of SOCE activity (e.g., Ca2þ influx, Mn2þ quench,
change in Ca2þ dye fluorescence trapped in t-tubules of
mechanically skinned fibers). In this study, we developed
a standardized electrophysiological approach to quantify
the SOCE current (ISkCRAC) in myotubes, validated the
measure according to multiple known biophysical, pharma-
cological, and molecular SOCE channel properties, and
used this direct measure of SOCE channel function to deter-
mine the role of temperature and ryanodine receptor func-
tionality on the rate of SOCE channel activation during
repetitive activation. The results show that increases in
ambient temperature and RyR1 Ca2þ release promote
ISkCRAC magnitude (RyR1) and rate of activation (RyR1
and temperature) during repetitive stimulation.SUPPORTING MATERIAL
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